With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Educational research only - not investment advice, an offer, or a trade instruction. Confirm current data and do your own due diligence before acting.
DHR trades against a final fair-value range of $122.72-$203.68, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.
Under severe bioprocessing market contraction and failed M&A execution, our pure intrinsic models force valuation toward the $114-$122 range. Margins revert below 19% as DBS efficiencies fail to offset volume deleverage, and the terminal multipleTerminal multipleThe exit P/E or EV/EBITDA we apply to the final year of an explicit forecast. Anchored to the business's long-run quality and the prevailing risk-free rate. contracts toward 15x as the compounding narrative breaks.
Extended pharma funding constraints and destocking cap revenue growth in low single-digits.
A major acquisition fails to realize DBS synergies, destroying ROIC and stalling margin expansion.
Deepening macro weakness and localized competition in China structurally erode regional market share and profitability.
| Line item | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
|---|---|---|---|---|---|---|
| Revenue | $24.80B | $26.64B+7.4% | $23.89B-10.3% | $23.88B-0.0% | $24.57B+2.9% | -0.2% |
| Gross profit | $15.24B | $16.19B | $14.03B | $14.21B | $14.52B | -1.2% |
| Operating income | $6.39B | $7.54B | $5.20B | $4.86B | $4.69B | -7.4% |
| Net income | $6.43B | $7.21B+12.1% | $4.76B-34.0% | $3.90B-18.1% | $3.61B-7.4% | -13.4% |
| EPS (diluted) | — | $9.66 | $6.38 | $5.29 | $5.05 | -15.0% |
| EBITDA | $8.80B | $9.48B | $7.50B | $7.28B | $6.95B | -5.8% |
| R&D | $1.50B | $1.53B | $1.50B | $1.58B | $1.60B | +1.6% |
| SG&A | $6.81B | $7.12B | $7.33B | $7.76B | $8.24B | +4.9% |
Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
| Deterioration versus the report thesis |
| Rising days sales outstanding in emerging markets | Monitor | Deterioration versus the report thesis |
| CapEx to depreciation ratio falling below 0.75 | Monitor | Deterioration versus the report thesis |
